Clinical Trial Update: A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating efalizumab (Raptiva) in adults with moderate to severe plaque psoriasis who are candidates for systemic therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED